Carcinotech
Edinburgh, GB · 12 known investors
Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
Founders & leadership
L
LornaChief Scientific Officer
A
Albert
I
Ian
S
Susanne
Investors · 12
Alba EquityAberdeen
TRICAPITALScottish Borders · $315K – $2.5M
British Business BankreportedSheffield
Eos AdvisoryreportedSt Andrews
Gabriel Investment Syndicatereported
Investing Women Angelsreported$335K
Maven CapitalreportedDubai · $700K – $6M
Maven Capital Partnersreported · 2 sourcesUK · $32K – $25M
Old College CapitalreportedEdinburgh · $190.5K
Scottish EnterprisereportedGlasgow
Also in the syndicate · 2
Investment Fund for Scotland (IFS)SIS Ventures
Companies House · registry record
View on Companies House ↗- Registered name
- CARCINOTECH LTD
- Company number
- SC604026
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 31 Jul 2018
- Registered office
- Roslin Innovation Centre, Easter Bush Campus, Edinburgh, Midlothian, EH25 9RG
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Jul 2026 · next due 13 Aug 2027
Current officers · 4
- Mbm Secretarial Services Limited — corporate secretary, appointed 23 Jan 2023
- Lorna Ewart — director, appointed 4 Jun 2024
- Albert Nicholl — director, appointed 2 Oct 2020
- Ian David Waddell — director, appointed 3 May 2022
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Carcinotech do?
- Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
- Who are Carcinotech's investors?
- Carcinotech's investors include Alba Equity, TRICAPITAL, British Business Bank, Eos Advisory, Gabriel Investment Syndicate, Investing Women Angels, Maven Capital, Maven Capital Partners and 2 more.
- Where is Carcinotech headquartered?
- Carcinotech is headquartered in Edinburgh, GB.